A randomized, controlled, open-label, Phase IIb/III study evaluating the combination of lurbinectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with metastatic leiomyosarcoma.
Principal Investigator
Dott.ssa Sandra Aliberti
Contact Information for Access
Phase
FASE III
Status
ATTIVO
Objective of the study
To compare the combination of Lurbinectidine + Doxorubicin with Doxorubicin alone by evaluating response according to RECIST, duration of response, survival, and clinical benefit in patients with metastatic leiomyosarcoma.
Metastatic leiomyosarcoma, no prior lines of treatment
ClinicalTrials.gov ID NCT06088290
Sponsor: PharmaMar
Pathologies
Sarcomi tumori rari e GIST
Medication
Lurbinectedin, Doxorubicin
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with histologically confirmed metastatic leiomyosarcoma who have not received prior systemic therapy for advanced disease and have not been treated with anthracyclines in a neoadjuvant or adjuvant setting.
View the full study Back to search page